Table 1. Clinico-pathological characteristics of patients with metastatic breast cancer with their respective CTC counts.
|
ISET
|
CellSearch | ||||||
|---|---|---|---|---|---|---|---|
| Patients a | Age b | Histology | ER/PR/HER2 status | TNM stage | CTC/7.5 ml | Atypical cells/7.5 ml | CTC/7.5 ml |
| B1 | 56 | IDC | ER−PR−HER2− | T2N0M0 | 6 | 25 | 14 |
| B2 | 49 | IDC | ER+PR+HER2− | T3N1M0 | 4 | 14 | 200 |
| B3 | 56 | ILC | ER+PR+HER2− | T3N2M0 | 20 | 165 | 25 500 |
| B4 | 39 | IDC | ER+PR+HER2− | TxNxM1 | 1 | 4 | 2 |
| B5 | 36 | IDCc | ER−PR−HER2− | T3N2M0 | 3 | 6 | 19 |
| B6 | 61 | IDC | ER+PR−HER2+ | T4dN2Mx | 1 | 0 | 2 |
| B7 | 49 | IDC | ER−PR−HER2+ | T4dN1M0 | 1 | 1 | 1078 |
| B8 | 70 | IDC | ER−PR−HER2+ | T2N1M0 | 0 | 1 | 1 |
| B9 | 43 | IDC | ER−PR−HER2+ | T2NxM1 | 2 | 2 | 1 |
| B10 | 68 | IDC | ER+HER2+ | TxN-M0 | 1 | 7 | 1 |
| B11 | 38 | IDC | ER−PR−HER2− | T2N0M0 | 0 | 2 | 0 |
| B12 | 68 | IDC | ER+PR+HER2− | T1cN1M0 | 1 | 12 | 1 |
| B13 | 43 | IDCd | ER+PR+HER2+ | T2N0Mx | 1 | 5 | 2 |
| B14 | 49 | IDC | ER−PR−HER2− | T2N0M0 | 4 | 17 | 0 |
| B15 | 76 | IDC | ER−PR−HER2− | T4dN0M0 | 2 | 18 | 0 |
| B16 | 61 | IDC | ER+PR−HER2− | T2N0Mx | 9 | 13 | 13 |
| B17 | 61 | IDC | ER+PR− | T2N1M0 | 5 | 13 | 0 |
| B18 | 56 | IDC | ER+ | T2N1M0 | 4 | 25 | 7 |
| B19 | 72 | IDC | ER+PR+HER2− | T4bN1M1 | 11 | 26 | 5 |
| B20 | 41 | IDC | ER+PR+HER2− | T3N1M0 | 0 | 2 | 0 |
Abbreviations: CTC=circulating tumour cell; ER=oestrogen receptor; F=female; HER2=human epidermal growth factor receptor 2; IDC=infiltrative ductal carcinoma; ILC=infiltrative lobular carcinoma; PR=progesterone receptor; TNM=tumour node metastasis.
a
All patients were female.
b
Age (years) at the moment of CTC analysis.
c
Infiltrative mucinous carcinoma.
d
Infiltrative apocrine carcinoma.
For patients B10, B17 and B18, PR, HER2 and PR and HER2 were not available, respectively.